alexa
Indianmoney.com Missed Call Number
 
Home News BoAML retains buy on Lupin after a launch of birth control drug

Read more interesting news from around the globe with Indianmoney App

Google Play
 
Get the Best Financial Advice on Business Insurance Click Here
 
BoAML retains buy on Lupin after a launch of birth control drug

BoAML retains buy on Lupin after a launch of birth control drug

Friday, March 17, 2017, 3:50 PM

Bank of America Merrill Lynch has maintained a buy rating on Lupin with a price target of Rs 1,920, implying 32% upside from current levels after the drug maker launched birth control drug in the US. The stock gained more than 1% intraday. The brokerage house expects generic Minastrin to contribute USD 100-50 million sales over FY18-19 at relatively high EBITDA margins of 80-85%.
Read More

Learn to Save, Spend, Invest & Borrow Wisely with our Youtube Channel

Get It now!